Ana M C De Jesus-Acosta

8PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 23, 2025
A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma.

Parul Agarwal, Matthew Guo, Kabeer Munjal

|May 19, 2025
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Eric S Christenson, Won Jin Ho, Daniel Shu

|Sep 04, 2024
Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice.

Ana De Jesus-Acosta, Chirayu Mohindroo

|Apr 25, 2024
Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors.

Chirayu Mohindroo, Seyda Baydogan, Parul Agarwal

|Aug 30, 2023
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer.

H Catherine Wilbur, Jennifer N Durham, Su Jin Lim

|Mar 27, 2023
Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma.

Eric S Christenson, Su Jin Lim, Jennifer Durham

Pageof 2